Teva slips as 2025 earnings outlook misses estimates
by
Contributor since / Followers
Contributor since / Followers
1 month ago
JHVEPhoto/iStock Editorial via Getty Images
Teva Pharmaceutical (NYSE:TEVA) lost ~5% in the premarket even after recording better-than-expected financials for Q4 2024 on Wednesday, as the generic drugmaker set its 2025 earnings outlook below consensus.
While TEVA’s revenue estimates for 2025 of $16.8B-$17.4B were in line with